Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03497767
Other study ID # TROG 17.02
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date August 15, 2019
Est. completion date March 2024

Study information

Verified date November 2022
Source Trans Tasman Radiation Oncology Group
Contact Trial Coordinator
Phone +61 2 401 43911
Email OUTRUN@trog.com.au
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

20-40% of patients with NSCLC will develop brain metastases at some point during their course of disease. Osimertinib has demonstrated intracranial activity in EFGR mutated NSCLC with leptomeningeal disease in the phase 1 BLOOM study. Stereotactic radiosurgery (SRS) is one of the standard local treatment for patients with limited number of brain metastases. Currently, it is unclear whether adding SRS to Osimertinib will result in superior intracranial disease control in patients with EGFR mutated NSCLC with brain metastases diagnosed de novo or developed while on first line EGFR tyrosine kinase inhibitors (TKIs) such as Erlotinib and Gefinitib. The aim of this study is to compare the effects of Osimertinib alone versus SRS plus Osimertinib on intra-cranial disease control in EGFR mutated NSCLC with brain metastases diagnosed or developed while on first line EGFR tyrosine kinase inhibitors.


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date March 2024
Est. primary completion date August 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Provided written informed consent 2. Has reached the age of majority in the country of treatment (i.e. = 18 years in Australia; = 21 years in Singapore) 3. Histological or cytological documented NSCLC 4. Metastatic NSCLC, not amenable to curative surgery or curative radiotherapy 5. Brain metastases that meet the following criteria; 1. = 10 lesion/s visible and measurable on protocol screening MRI; - At least one brain metastases able to be treated with SRS - Definite but small brain metastases not for SRS treatment due to size, as per physician discretion, are included in the total - Equivocal small lesions are not included in the total 2. No single brain metastasis exceeding 30mm longest diameter 3. Total brain metastasis volume = 15cc; - Total brain metastases volume on protocol screening MRI should be using the formula (4/3) x (3.14159265359) x (1/2 x size lesion in centimetre)3. Table 1: Brain metastases volume estimates provides an estimate of the volume of brain metastases based on the size of the lesion 4. Diagnosed de novo (i.e. at the same time with a new diagnosis of NSCLC) or developed as a new site of progression while on first line EGFR TKI NOTE: Surgery as part of local practice for the management of brain metastasis is allowed but must be completed between 2 to 4 weeks prior to randomisation. Patients must still fulfil criteria 5a, 5b and 5d pre-surgery, and have at least one target lesion post-surgery to be eligible for the study. Lesions that are partially or completely resected should not be used as a target lesion for MRI assessment. 6. Documented EGFR mutation; 1. Patients who developed brain metastases as a site of disease progression while on first line EGFR TKIs must have T790M mutation. 2. Documented EGFR mutation (at any time since the initial diagnosis of NSCLC) known to be sensitive to Osimertinib - These include exon 19 del; L858R (exon 21); G719X (exon 18); L861G (exon 21); S768I (exon 20) and T790M (exon 20) NOTE: Mutation analysis is to be done as per local practice. Please see section 7.1.1 for the recommended clinical practice for analysis. 7. Are one of the following cohorts: 1. First-line metastatic cancer: All newly diagnosed participants with documented sensitising EGFR mutation (criterion 6) and intracranial metastasis (criterion 5), with/without extracranial disease 2. Second-line metastatic cancer (T790M+): Participants who progressed after first-line 1st or 2nd generation EGFR TKI therapy with intracranial progression (criterion 5), with/without extracranial disease and have documented T790M mutation 3. Second-line metastatic cancer (T790M-): Participants with no T790M mutation who progressed after first-line 1st or 2nd generation EGFR TKI therapy with intracranial progression (criterion 5) but has no extracranial disease 4. Second-line metastatic cancer (T790M-): Participants with no T790M mutation who progressed after first-line 1st or 2nd generation EGFR TKI therapy with intracranial progression (criterion 5) but has stable extracranial disease 8. Karnofsky performance status 60-100 (ECOG performance status =2) with no deterioration over the previous 2 weeks and a minimum life expectancy of 12 weeks 9. Female patients who; 1. are willing to use adequate contraceptive measures until 6 weeks after the final dose of study treatment 2. are not breast feeding 3. have a negative pregnancy test prior to the start of dosing if of child bearing potential or have evidence of non-child bearing potential by fulfilling one of the following criteria at screening: i. Post-menopausal defined as aged more than 50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments ii. Women under 50 years old would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and with Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) levels in the post-menopausal range for the institution iii. Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation 10. Male patients who are willing to use barrier contraception (i.e. condoms) until 4 months after the final dose of study treatment Exclusion criteria: 1. Treatment with any of the following: 1. Prior systemic therapy for patients with newly diagnosed metastatic NSCLC and brain metastases de novo. NOTE: Prior adjuvant chemotherapy or chemotherapy used as radio sensitisation followed by maintenance immunotherapy for non-resectable early stage NSCLC are allowed if such treatments were more than 6 months ago. 2. Prior whole brain radiotherapy (WBRT) 3. Radiologically progressive brain metastasis that underwent prior SRS (second line patients) 4. Previous treatment with Osimertinib or a 3rd generation EGFR TKI. 5. Previous treatment with checkpoint inhibitors immunotherapy for metastatic NSCLC. 6. Major surgery within 4 weeks of randomisation (excluding placement of vascular access and surgery as part of local practice for the management of brain metastases, as outlined in inclusion criterion 5). 7. Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of randomisation. 8. Medications or herbal supplements known to be potent inducers of CYP3A4 and are unable to stop use within the recommended wash out period prior to receiving the first dose of Osimertinib, see Table 7: Medications to avoid and withdrawal periods and Table 8 NOTE: All patients must try to avoid concomitant use of any medications, herbal supplements and/or ingestion of foods with known inducer effects on CYP3A4 9. An investigational drug within five half-lives of the compound or 3 months, whichever is greater. 10. Any other cytotoxic chemotherapy, investigational agents or other anticancer drugs from a previous treatment regimen or clinical study within 14 days of randomisation. 2. Any unresolved toxicities from prior therapy greater than CTCAE grade 1 (with the exception of alopecia grade 2) at the time of starting study treatment. 3. Spinal cord compression unless asymptomatic and stable. 4. Leptomeningeal disease. 5. Moderate or severe symptomatic brain metastases defined as per Radiation Therapy Oncology Group acute morbidity grade 3 to 4. NOTE: - Grade 3 refers to neurological findings requiring hospitalisation for initial management. - Grade 4 refers to serious neurological impairment including paralysis, coma or seizures more than three times per week despite medication and requires hospitalization. 6. Brain metastases in the brainstem. 7. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the protocol, or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV). Screening for chronic conditions is not required. 8. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of Osimertinib. 9. Any of the following cardiac criteria: 1. Resting corrected QT interval (QTc) > 470 msec, obtained from an electrocardiogram (ECG). 2. Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG e.g. complete left bundle branch block, third degree heart block or second degree heart block. 3. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, electrolyte abnormalities (including: Serum/plasma potassium < LLN; Serum/plasma magnesium < LLN; Serum/plasma calcium < LLN), congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval. 10. Patients with congenital long QT syndrome (CLQTS) 11. Past medical history of Interstitial Lung Disease (ILD), drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease. 12. Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values: 1. Absolute neutrophil count < 1.5 X 109/L 2. Platelet count < 100 X 109/L 3. Haemoglobin < 90 g/L 4. Alanine aminotransferase (ALT) > 2.5 times the upper limit of normal (ULN) if no demonstrable liver metastases or > 5 times ULN in the presence of liver metastases 5. Aspartate aminotransferase (AST) > 2.5 times ULN if no demonstrable liver metastases or > 5 times ULN in the presence of liver metastases. 6. Total bilirubin > 1.5 times ULN if no liver metastases or > 3 times ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinemia) or liver metastases. 7. Creatinine > 1.5 times ULN concurrent with creatinine clearance < 50ml/min (measured or calculated by Cockcroft and Gault equation); confirmation of creatinine clearance is only required when creatinine is > 1.5 times ULN. 13. History of hypersensitivity of drugs with a similar chemical structure or class to Osimertinib or any excipients of these agents. 14. Involvement in the planning and conduct of the study 15. Judgement by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Osimertinib
All participants will receive a dose of Osimertinib 80mg once daily
Radiation:
Stereotactic Radiosurgery (SRS)
Dose and fractionation depend on lesion size. All SRS must be completed within 21 days of randomisation and all lesions are to be treated within 7 days.

Locations

Country Name City State
Australia Royal Adelaide Hospital Adelaide South Australia
Australia ICON Cancer Centre Greenslopes Brisbane Queensland
Australia Princess Alexandra Hospital Brisbane Queensland
Australia Monash Health Melbourne Victoria
Australia Peter MacCallum Cancer Center Melbourne Victoria
Australia Calvary Mater Newcastle New South Wales
Australia Sir Charles Gairdner Perth Western Australia
Australia Blacktown Hospital Sydney New South Wales
Australia Liverpool Hospital Sydney New South Wales
Australia St George Hospital Sydney New South Wales
Australia St. Vincents Hospital Sydney New South Wales
Australia Westmead Hospital Sydney New South Wales
Singapore National University Hospital Singapore

Sponsors (1)

Lead Sponsor Collaborator
Trans Tasman Radiation Oncology Group

Countries where clinical trial is conducted

Australia,  Singapore, 

Outcome

Type Measure Description Time frame Safety issue
Primary Intracranial progression free survival at 12 months To assess the efficacy of Osimertinib with deferred local brain metastases directed therapies compared with upfront SRS followed by Osimertinib by assessment of intracranial progression free survival at 12 months. 12 months post randomisation
Secondary Use of salvage whole-brain radiotherapy (WBRT) To assess the effect of Osimertinib with deferred local brain metastases directed therapies compared with upfront SRS followed by Osimertinib on use of salvage whole-brain radiotherapy (WBRT) +/- neurosurgery. 18 months post randomisation
Secondary Local brain failure To assess the effect of Osimertinib with deferred local brain metastases directed therapies compared with upfront SRS followed by Osimertinib on local brain failure. 18 months post randomisation
Secondary Distant brain failure To assess the effect of Osimertinib with deferred local brain metastases directed therapies compared with upfront SRS followed by Osimertinib on distant brain failure. 18 months post randomisation
Secondary Extra-cranial progression To assess the effect of Osimertinib with deferred local brain metastases directed therapies compared with upfront SRS followed by Osimertinib on extra-cranial progression. 18 months post randomisation
Secondary Overall Survival To further assess the efficacy of Osimertinib with deferred local brain metastases directed therapies compared with upfront SRS followed by Osimertinib in terms of overall survival. 18 months post randomisation
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04965090 - A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC) Phase 2
Recruiting NCT06060613 - Safety and Efficacy of OBX-115 in Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT04884282 - Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED) Phase 2
Recruiting NCT05236608 - A Study to Evaluate the Combination of Nivolumab With ADG106 in Metastatic NSCLC Phase 1/Phase 2
Recruiting NCT04614103 - Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer Phase 2
Recruiting NCT05215340 - Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations Phase 3
Not yet recruiting NCT06066138 - A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing Phase 1
Not yet recruiting NCT06068153 - AMG510 (Sotorasib) Plus Lenvatinib as Second-line Treatment in Patients With KRASG12C Mutant, Metastatic NSCLC Phase 2
Recruiting NCT05429320 - A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC) Phase 2
Recruiting NCT05478538 - Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform
Completed NCT01773109 - Etirinotecan Pegol (NKTR-102) in NSCLC Phase 2
Recruiting NCT04743505 - Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) Phase 1/Phase 2
Recruiting NCT05111197 - Local Ablative Stereotactic Radiotherapy for Residual Hypermetabolic Lesion in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Long-term Responders to Immunotherapy Phase 3
Recruiting NCT05555732 - Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) Phase 3
Recruiting NCT05676749 - C-TIL051 in Non-Small Cell Lung Cancer Phase 1
Not yet recruiting NCT05566223 - CISH Inactivated TILs in the Treatment of NSCLC Phase 1/Phase 2
Terminated NCT01060514 - Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer Phase 1
Completed NCT05167500 - Efficacy & Safety Study of Lorlatinib in ALK/ROS1 Metastatic NSCLC Patients With Compassionate Use Treatment
Recruiting NCT05259319 - Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT) Phase 1
Enrolling by invitation NCT04697446 - External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC

External Links